Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
5.64
-0.22 (-3.75%)
At close: Nov 13, 2025, 4:00 PM EST
5.64
0.00 (0.00%)
After-hours: Nov 13, 2025, 4:10 PM EST
Nutriband Revenue
Nutriband had revenue of $622.45K in the quarter ending July 31, 2025, with 40.56% growth. This brings the company's revenue in the last twelve months to $2.58M, up 42.92% year-over-year. In the fiscal year ending January 31, 2025, Nutriband had annual revenue of $2.14M with 2.60% growth.
Revenue (ttm)
$2.58M
Revenue Growth
+42.92%
P/S Ratio
25.32
Revenue / Employee
$198,312
Employees
13
Market Cap
67.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jan 31, 2025 | 2.14M | 54.22K | 2.60% |
| Jan 31, 2024 | 2.09M | 5.71K | 0.27% |
| Jan 31, 2023 | 2.08M | 657.46K | 46.23% |
| Jan 31, 2022 | 1.42M | 478.45K | 50.70% |
| Jan 31, 2021 | 943.70K | 573.06K | 154.61% |
| Jan 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NTRB News
- 16 days ago - REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 16 days ago - Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 4 weeks ago - Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 5 weeks ago - Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology - GlobeNewsWire
- 5 weeks ago - Nutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference - GlobeNewsWire
- 7 weeks ago - Nutriband Inc. to Present at the MicroCap Rodeo Conference - GlobeNewsWire
- 2 months ago - Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - GlobeNewsWire
- 2 months ago - Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000 - GlobeNewsWire